<DOC>
	<DOCNO>NCT00859547</DOCNO>
	<brief_summary>The objective study assess safety immunogenicity recombinant thrombin ( rThrombin ) administer aid hemostasis burn wound excision skin graft pediatric patient , newborn 17 year age .</brief_summary>
	<brief_title>Safety Immunogenicity Study Recombinant Thrombin ( rThrombin ) Pediatric Participants</brief_title>
	<detailed_description>The safety , immunogenicity , efficacy rThrombin evaluate 5 Phase 2 study , 1 pivotal Phase 3 study , 1 Phase 3b study , surgical indication : spinal surgery , major hepatic resection , peripheral arterial bypass surgery , arteriovenous graft formation hemodialysis access , burn wound excision . Limited data currently exist effect rThrombin exposure pediatric patient . This Phase 4 trial aim provide additional information use rThrombin child evaluate drug 's safety immunogenicity administer aid hemostasis burn wound excision skin graft pediatric burn patient .</detailed_description>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Age newborn 17 year time enrollment At least 1 skin graft recipient site measure least 1 % total body surface area ( TBSA ) Total initial burn wound estimate measure le 40 % TBSA Bleeding indicate treatment rThrombin surgical procedure Females childbearing potential must negative urine serum pregnancy test within 2 day prior studydrug treatment inform consent document sign legal representative ( guardian ) approve institutional review board/independent ethic committee ( IRB/IEC ) Participant sign IRB/IECapproved pediatric assent document , applicable Gestational age younger 36 week birth ( infant younger 2 year ) Documented active infection graft recipient site ( participant resolve infection potential graft recipient site exclude ) Acute inhalation injury , define bronchoscopic evidence low airway injury Currently undergo autologous skin graft ischemic ulcer disease cutaneous malignancy Presence antibody hypersensitivity study drug component , thrombin preparation , coagulation factor Transfusion whole blood , fresh frozen plasma , cryoprecipitate , platelet within 24 hour prior studydrug treatment ( pack red blood cell transfusion allow ) History HIV infection immunodeficiency syndrome take immunosuppressive antirejection medication Medical , social , psychosocial factor , opinion investigator , could affect safety compliance study procedure Breastfeeding breastfed Treatment experimental agent within 30 day study enrollment treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>